NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
OTC · AGTX · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Agentix Corp.’s quoted price sits in the upper half of its reported 52-week range, 24.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Agentix Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Agentix Corp., a company in the clinical development phase, specializes in the discovery and commercialization of therapeutic agents aimed at treating metabolic disorders. Its pipeline includes two primary candidates: AGTX-2004, a peripherally-acting CB1 receptor antagonist, which has exhibited effectiveness in animal studies for both obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, also demonstrating positive results in animal models for obesity and non-alcoholic fatty liver diseases. The company was founded in 2013, initially known as FairWind Energy, Inc., before officially changing its name to Agentix Corp. in June 2019. Its operations are based in Dana Point, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$12.15+$0.08 (+0.66%)
Arcturus Therapeutics Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.35% below the high.
CA$0.81-CA$0.01 (-1.22%)
Arch Biopartners Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.14% below the high.
$0.39-$0.02 (-5.66%)
Reviva Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.46% below the high.
$0.06+$0.02 (+50.0%)
ADM Tronics Unlimited, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.03$0.00 (0.0%)
Acro Biomedical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 74.0% below the high.
$0.00$0.00 (0.0%)
Aditxt, Inc.’s quoted price sits in the lower half of its reported 52-week range, 100.0% below the high.
$0.00$0.00 (0.0%)
Alterola Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.9% below the high.
